irinotecan has been researched along with Dihydrotanshinone I in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, RL; Cho, CH; Hu, T; Li, M; Lu, L; Shen, J; To, KK; Wang, L; Yeung, JH; Zhang, L | 1 |
| Du, GH; Wang, L; Wang, R; Wang, SM; Wei, GY | 1 |
2 other study(ies) available for irinotecan and Dihydrotanshinone I
| Article | Year |
|---|---|
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Camptothecin; Digoxin; Doxorubicin; Drugs, Chinese Herbal; Furans; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Phenanthrenes; Quinones; Salvia miltiorrhiza | 2014 |
Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colon; Diglycerides; Disease Models, Animal; Feces; Fluorouracil; Furans; Gastrointestinal Microbiome; Interleukin-6; Intestinal Mucosa; Irinotecan; Male; Mice, Inbred C57BL; Mucositis; Phenanthrenes; Quinones; Triglycerides; Tumor Necrosis Factor-alpha | 2020 |